ライフサイエンスコーパス: antiviral drug

1 but it lacks a licensed vaccine or suitable antiviral drug.

2 ivo under selective pressure by a host-based antiviral drug.

3 he potential to function as a broad-spectrum antiviral drug.

4 ny of them, there is no effective vaccine or antiviral drug.

5 en that lacks a licensed vaccine or suitable antiviral drug.

6 d and developed into a potent broad-spectrum antiviral drug.

7 se (NA) is a major target for small-molecule antiviral drugs.

8 ial avenues for the development of alternate antiviral drugs.

9 ural 5A protein (NS5A) is the target for new antiviral drugs.

10 as a valuable tool for evaluating promising antiviral drugs.

11 attenuation and new targets for screening of antiviral drugs.

12 dying pathogenicity, immunity, vaccines, and antiviral drugs.

13 immunity, develop novel vaccines, or develop antiviral drugs.

14 ses, HBx represents an attractive target for antiviral drugs.

15 developing LIMK inhibitors as broad-spectrum antiviral drugs.

16 atitis C virus (HCV) vaccines and affordable antiviral drugs.

17 ce necessitate the development of new potent antiviral drugs.

18 esent great potential for the development of antiviral drugs.

19 thus a primary target for the development of antiviral drugs.

20 , there is an urgent need for more effective antiviral drugs.

21 r compound testing, including potential ZIKV antiviral drugs.

22 ckaging might lead to the development of new antiviral drugs.

23 he rational design of vaccines and potential antiviral drugs.

24 g virus are essential for the development of antiviral drugs.

25 lysis and development of novel antitumor and antiviral drugs.

26 n sensory neurons and cannot be cleared with antiviral drugs.

27 ing is a novel target for the development of antiviral drugs.

28 ality largely because of a lack of effective antiviral drugs.

29 g pathways potential therapeutic targets for antiviral drugs.

30 e interactions may represent new targets for antiviral drugs.

31 o find new treatments beyond vaccination and antiviral drugs.

32 ed for a next generation of highly effective antiviral drugs.

33 ns could facilitate the development of novel antiviral drugs.

34 and the development of resistance to current antiviral drugs.

35 eral strains with variable susceptibility to antiviral drugs.

36 table levels of viremia despite not being on antiviral drugs.

37 t round of rational design of broad-spectrum antiviral drugs.

38 road-spectrum targets for the development of antiviral drugs.

39 selective pressure, such as the presence of antiviral drugs.

40 sets the stage for designing E inhibitors as antiviral drugs.

41 determine the efficacy of novel or available antiviral drugs.

42 e used to test preclinically the efficacy of antiviral drugs.

43 tion as potent broad-spectrum, host-oriented antiviral drugs.

44 lts should accelerate the design of specific antiviral drugs.

45 methods and combination therapies with other antiviral drugs.

46 ional design of live attenuated vaccines and antiviral drugs.

47 nd the molecular assessment of resistance to antiviral drugs.

48 ion, and are considered critical targets for antiviral drugs.

49 , the RSV RdRP is a logical target for novel antiviral drugs.

50 atform for future development and testing of antiviral drugs.

51 logical suppression of HIV in the absence of antiviral drugs.

52 re attractive targets for the development of antiviral drugs.

53 that could be targeted in the development of antiviral drugs.

54 sease and/or the cessation or reduced use of antiviral drugs.

55 starvation, and uncovers common targets for antiviral drugs.

56 In this study, the removal of five antiviral drugs (abacavir, acyclovir, emtricitabine, lam

57 inhibition of C/EBPbeta expression with the antiviral drug adefovir dipivoxil attenuated TGFbeta-med

58 for the clinical development of UV-4B as an antiviral drug against DENV, and it provides a framework

59 eviously reported, ribavirin is an effective antiviral drug against many RNA viruses.

60 t can serve as a novel target for developing antiviral drugs against arenavirus pathogens.

61 ave the potential for further development as antiviral drugs against CHIKV infection.

62 as a potential target in the development of antiviral drugs against EBOV.

63 n 3 position of pyrimidine ring as potential antiviral drugs against HCV.

64 opment of novel prophylactic and therapeutic antiviral drugs against hRSV is imperative to control th

65 Although antiviral drugs against influenza viruses have been deve

66 Certain IN mutations (class II) and antiviral drugs (allosteric IN inhibitors [ALLINIs]) adv

67 Moreover, binding of the antiviral drug, amantadine, at the N-terminal pore at lo

68 st that atovaquone could be a broad-spectrum antiviral drug and a potential attractive candidate for

69 unique target for developing a novel type of antiviral drug and improved options of broad-spectrum an

70 Some antiviral drugs and broadly reactive influenza vaccines

71 will likely require the broad application of antiviral drugs and development of an effective vaccine.

72 ng virus-host interactions can lead to novel antiviral drugs and enhanced vaccine production.

73 esis and to assess the efficacy of candidate antiviral drugs and new vaccines.IMPORTANCE Early pathog

74 pre-emptive therapy with lamivudine or other antiviral drugs and no one showed episodes of viral reac

75 There are no antiviral drugs and no preventive vaccine.

76 titutes a promising target for host-directed antiviral drugs and possibly other autophagy-sensitive c

77 ction, as well as help in the development of antiviral drugs and protective vaccines.

78 mall-primate animal model for studying novel antiviral drugs and T-cell-based vaccines against HCV in

79 will likely require the broad application of antiviral drugs and the development of an effective vacc

80 Phototransformation rates of parent antiviral drugs and their biotransformation products wer

81 infection, to repurpose currently available antiviral drugs and to develop new therapies and vaccine

82 though far less advanced than for influenza, antiviral drugs and vaccines are in different stages of

83 This encourages targeting the HA stalk with antiviral drugs and vaccines as well as reevaluating pre

84 With limited antiviral drugs and vaccines available, vector control i

85 impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs.

86 and boost research and development into new antiviral drugs and vaccines for these viruses.

87 Although antiviral drugs and vaccines have reduced the economic a

88 ins, is direly needed for the development of antiviral drugs and vaccines.

89 rational design of novel and highly specific antiviral drugs and will aid in the detailed understandi

90 used to study polio pathogenesis, candidate antiviral drugs, and the efficacy of new vaccines.

91 re critical for basic research, diagnostics, antiviral drugs, and vaccines to combat IBV.

92 be effectively treated with a broad-spectrum antiviral drug approved for use in Japan.

93 Currently, there are no licensed vaccines or antiviral drugs approved for human use.

94 The antiviral drug arbidol (ARB), already in clinical use in

95 The broad-spectrum antiviral drug Arbidol shows efficacy against influenza

96 Antiviral drugs are a proposed medical intervention to r

97 Current antiviral drugs are associated with a significant toxici

98 ; yet currently, no vaccines or FDA-approved antiviral drugs are available to counter these pathogens

99 ry illness for which no vaccines or suitable antiviral drugs are available.

100 However, no specific vaccines or antiviral drugs are currently available to prevent or tr

101 Antiviral drugs are effective against severe VZV infecti

102 le-genome sequencing of virus.IMPORTANCE New antiviral drugs are needed as a first line of defense in

103 Antiviral drugs are needed for clinical practice and pub

104 viral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing vi

105 Licensed vaccines or suitable antiviral drugs are not available.

106 national economies as effective vaccines or antiviral drugs are not currently available (according t

107 Because antiviral drugs are of limited efficacy in patients hosp

108 In addition to vaccination, however, antiviral drugs are required for individuals with uncert

109 Current antiviral drugs are susceptible to drug resistance, and

110 Four antiviral drugs are used for preventing or treating CMV:

111 Available antiviral drugs are virus-specific and active against a

112 diagnostics, and identification of candidate antiviral drugs argue that the major obstacles to drug d

113 ed with oral corticosteroids alone, are oral antiviral drugs associated with improved outcomes when c

114 results with favipiravir demonstrate that an antiviral drug at nontoxic doses exhibits a marked prote

115 ignificance for which there is no vaccine or antiviral drug available.

116 Currently, there are no vaccines or antiviral drugs available for NoV infection.

117 (NA) inhibitors (NAIs) are the only class of antiviral drugs available for therapeutic intervention f

118 Currently, there are no vaccines or antiviral drugs available to counter these highly contag

119 y of these viruses, there are no vaccines or antiviral drugs available.

120 f these synergistic interactions is with the antiviral drug azidothymidine (AZT).

121 tantial differences in kinetics of different antiviral drugs, biotransformation reactions mainly invo

122 not only to suppress viral replication with antiviral drugs but also potentially to eliminate or "cu

123 Addition of a third potent direct-acting antiviral drug can reduce the duration of treatment requ

124 Because antiviral drugs can have side effects and show reduced c

125 affirm that M2-S31N inhibitors are promising antiviral drug candidates that warrant further developme

126 The antiviral drug cidofovir improved survival in MCMV+ mice

127 ent data and the addition of host factor and antiviral drug components.

128 t RNA polymerase, which is a major target of antiviral drugs currently in the clinic.

129 Phase 3 trials of direct acting antiviral drugs (DAAs) for hepatitis C virus (HCV) exclu

130 All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have

131 es the use of highly effective direct-acting antiviral drugs (DAAs) to achieve elimination by 2030.

132 Development of broad-spectrum antiviral drugs depends on a better mechanistic understa

133 provides insights into specific targets for antiviral drug design for improved efficacy.

134 ad in the long run to a structural basis for antiviral drug design.

135 y CpAMs, indicating a more complex basis for antiviral drug design.

136 tures and mechanisms that can be targeted in antiviral drug design.

137 nstructural proteins, offers new avenues for antiviral drug design.

138 anscription and represents a focal point for antiviral drug design.

139 Antiviral drugs designed to accelerate viral mutation ra

140 Antiviral drug development against respiratory syncytial

141 ch has implications for vaccine manufacture, antiviral drug development, and pandemic risk assessment

142 dings may provide a new structural basis for antiviral drug development.

143 and entry, serving as promising targets for antiviral drug development.

144 r VZV skin infection and may be targeted for antiviral drug development.

145 ich is a potential target for broad-spectrum antiviral drug development.

146 replication and could be a target for broad antiviral drug development.

147 a new, potentially broad-spectrum target for antiviral drug development.

148 revealing a potential target of lipid based antiviral drug development.

149 model is a critical step in the path toward antiviral drug development.

150 o identify targetable host factors and guide antiviral drug development.

151 cation and reveals a novel target for potent antiviral drug development.

152 ying ac4C addition as a potential target for antiviral drug development.

153 ntial broad utility for rapid diagnostic and antiviral drug development.

154 One of the promising targets for antiviral drug discovery against dengue and related flav

155 put based assays are beginning to accelerate antiviral drug discovery and improve on current strategi

156 cription that PKD may represent a target for antiviral drug discovery.

157 HBV replication and an important target for antiviral drug discovery.

158 pathogenesis and considerable investment in antiviral drug discovery.

159 assembly and identify potential targets for antiviral drug discovery.

160 tcomes, but was rather associated with lower antiviral drug exposure (6.4 +/- 13 days vs 38.6 +/- 14

161 a murine CMV that is highly sensitive to the antiviral drug famciclovir to modulate virus replication

162 Food and Drug Administration (FDA)-approved antiviral drug for which genotypic resistance analyses w

163 There is an unmet need in developing novel antiviral drugs for better control of IAV infection.

164 To develop potentially prophylactic antiviral drugs for combating these acute infectious dis

165 Antiviral drugs for managing infections with human coron

166 There are no vaccines or antiviral drugs for most of these viruses.

167 develop live attenuated vaccines as well as antiviral drugs for pneumoviruses.

168 novel, live attenuated vaccines, as well as antiviral drugs for pneumoviruses.

169 target for the development of direct-acting antiviral drugs for the treatment of chronic HCV infecti

170 New direct-acting antiviral drugs for the treatment of chronic hepatitis C

171 search for human adenovirus (HAdV)-specific antiviral drugs for the treatment of HAdV infections in

172 dates for the development of a new family of antiviral drugs for the treatment of infections by DNA v

173 ions that should facilitate the discovery of antiviral drugs for this important zoonotic pathogen.

174 There are no approved vaccines or antiviral drugs for treatment of infected patients.

175 xycytidine analogs, have been widely used as antiviral drugs for years, a structural basis for D-ster

176 idine (telbivudine) have been widely used as antiviral drugs for years.

177 potential in various applied areas, e.g. as antiviral drugs, for the vaccine development and as nove

178 Here we show that the FDA-approved antiviral drug ganciclovir (GCV) induces a type I interf

179 ted with supportive therapy and experimental antiviral drug GS-5734 (Gilead Sciences, San Francisco,

180 However, no vaccine or antiviral drug has been approved yet.

181 No specific antiviral drug has been proven effective for treatment o

182 Direct-acting antiviral drugs have a high cure rate and favourable tol

183 Unlike AM2, no antiviral drugs have been developed to block the BM2 cha

184 2018) toward the identification of selective antiviral drugs have been primarily focused on antiviral

185 al; however, small-molecule orally available antiviral drugs have yet to be developed.

186 nd function of AM2, which is targeted by two antiviral drugs, have been well characterized.

187 d provide new targets for the development of antiviral drugs.IMPORTANCE Porcine reproductive and resp

188 e developed as a new class of broad-spectrum antiviral drugs.IMPORTANCE The actin cytoskeleton is a s

189 critically evaluate the rationale for using antiviral drugs in the treatment of patients with glioma

190 reported the effectiveness of direct-acting antiviral drugs in these patients.

191 Antiviral drugs including maribavir and letermovir are i

192 It is a major target for antiviral drugs including nucleoside analogs, such as th

193 To date, no specific antiviral drug is available to treat or prevent this dis

194 A vaccine or generally effective antiviral drug is not yet available.

195 A wide range of antiviral drugs is currently available; however, drug-re

196 of the virus genome, resistance to available antiviral drugs is frequently observed, and new targets

197 DNA and L-dCTP or the triphosphate forms of antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine

198 using the triphosphates of chain-terminating antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine

199 Moreover, current highly effective antiviral drugs make efforts to treat hepatitis C with h

200 Furthermore, treatment with one antiviral drug might promote the development of antivira

201 xanthine alkaloids, nucleosides, and related antiviral drug molecules.

202 With no antiviral drugs nor vaccines, and the presence of carrie

203 Poliovirus antiviral drugs offer the only mitigation of these risks

204 ung children for which there are no suitable antiviral drugs offered.

205 efficacy and safety of the two direct-acting antiviral drugs ombitasvir, an NS5A inhibitor, and parit

206 showed that treatment of pregnant women with antiviral drugs or hyperimmunoglobulins significantly re

207 uld be a target for development of new small antiviral drugs or peptidomimetics.

208 Additionally, no antiviral drugs or vaccines were developed against the c

209 0 years, there are no commercially available antiviral drugs or vaccines.

210 Furthermore, the antiviral drug oseltamivir is less effective for treatin

211 ses that were resistant and sensitive to the antiviral drug oseltamivir, resistance was propagated th

212 nfluence of HBV genotypes on the response to antiviral drugs, particularly TDF, is poorly understood.

213 dies of ALI and ARDS to evaluate vaccine and antiviral drug performance, including in the most vulner

214 ve care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemen

215 The antiviral drug remdesivir has been shown clinically effe

216 The antiviral drug remdesivir, dexamethasone, transfusion of

217 ommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopina

218 time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available, and unfortunat

219 Antiviral drugs represent important means of influenza v

220 ctions and facilitate future applications in antiviral drug research to manage flavivirus infections.

221 treatment failure upon standard care due to antiviral drug resistance and treatment-limiting side ef

222 Antiviral drug resistance in influenza infections has be

223 Development of antiviral drug resistance is a continuous concern for vi

224 sitic nature of viruses and the emergence of antiviral drug resistance necessitate the development of

225 Antiviral drug resistance should be suspected when CMV v

226 nts may predict CMV infection resolution and antiviral drug resistance.

227 idate a previously unidentified mechanism of antiviral drug resistance.

228 tide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high respon

229 on renders the virus more susceptible to the antiviral drug ribavirin, suggesting that recombination

230 mechanism of resistance of a poxvirus to the antiviral drug rifampin.

231 CL(pro) This reporter-based assay allows for antiviral drug screening in human cell culture at biosaf

232 mentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosaf

233 vailable for CMV infection and the available antiviral drugs suffer from toxicity, poor efficacy and

234 investigate the impact of this tryptophan on antiviral drug susceptibility and viral replicative capa

235 esent here will allow future studies on EV71 antiviral drug susceptibility, vaccine efficacy, transmi

236 hese results have important implications for antiviral drug susceptibility, vaccine efficacy, transmi

237 investigate the impact of this tryptophan on antiviral drug susceptibility.

238 hese findings implicate EV-D68 2A(pro) as an antiviral drug target and highlight the repurposing pote

239 he mammalian SKI complex as a broad-spectrum antiviral drug target and identifies lead compounds for

240 research aims to increase the efficiency of antiviral drug target discovery using existing protein-p

241 AM2 S31N is a high-profile antiviral drug target, as more than 95% of currently cir

242 To further confirm the antiviral drug target, serial viral passage experiments

243 Because AAK1 is a promising antiviral drug target, we have embarked on an optimizati

244 RT-IN interaction can be exploited as a new antiviral drug target.

245 ractions and highlight their potential as an antiviral drug target.

246 complex is a broad-spectrum, host-directed, antiviral drug target.

247 tease (Mpro) is an attractive broad-spectrum antiviral drug target.

248 king to validate this protein as a potential antiviral drug target.

249 elp to guide the development of vaccines and antiviral drugs targeting astrovirus.

250 de a small-animal model for evaluating novel antiviral drugs targeting HCV NS3-NS4A protease and T-ce

251 The use of antiviral drugs targeting host proteins required for vir

252 this finding, we reviewed the development of antiviral drugs targeting viral DNA-packaging motors.

253 not only will facilitate the development of antiviral drugs targeting viral entry steps but also wil

254 al and human DEDDh exonucleases can serve as antiviral drug targets due to their critical roles in vi

255 hange factor 1 (GBF1) and JAK1, as potential antiviral drug targets.

256 e recommended for further study as potential antiviral drug targets.

257 development of a new efficient synthesis of antiviral drug telaprevir.

258 Nelfinavir (NFV) is a clinically important antiviral drug that inhibits production of infectious HI

259 Favipiravir is a broad-spectrum antiviral drug that may be used to treat influenza.

260 HV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic vi

261 his shift was blocked by ribavirin (RBV), an antiviral drug that reduces relapse in HCV patients.

262 both targets for highly potent and promising antiviral drugs that are in the late stages of clinical

263 g of the mode of action of the highly potent antiviral drugs that are targeted to NS5A.

264 tates exploring novel targets for developing antiviral drugs that can reduce the global burden of inf

265 rse combination therapies with direct-acting antiviral drugs that might be explored in future clinica

266 led to development of many new direct-acting antiviral drugs that target key components of virus repl

267 indings can lead to the development of novel antiviral drugs that target viral genomes and block vira

268 es it a major unmet target for a vaccine and antiviral drug therapy.

269 al reactivation in order to be vulnerable to antiviral drugs, these findings identify a new way to in

270 e are no approved vaccines and few effective antiviral drugs; thus, a safe and efficacious RSV therap

271 hether the addition of a third direct-acting antiviral drug to sofosbuvir and ledipasvir would allow

272 onceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA

273 velopment of orally available broad-spectrum antiviral drugs to stop the current pandemic and prevent

274 effect of glycans on the binding kinetics of antiviral drugs to the influenza neuraminidase.

275 t groundwork for the eventual development of antiviral drugs to treat AIDS.

276 There is a great need for antiviral drugs to treat enterovirus (EV) and rhinovirus

277 Currently, there are no effective antiviral drugs to treat RSV infection.

278 hesis, and nucleoside-derived anticancer and antiviral drug transport in humans.

279 Current antiviral drugs treat only a small number of viral disea

280 on cannot be cured since neither vaccine nor antiviral drug treatments are available.

281 r education, barrier methods, and the costly antiviral drug treatments, eliminating or at least reduc

282 This hidden provirus is protected from antiviral drugs until it eventually reactivates to produ

283 ses of Food and Drug Administration-approved antiviral drugs used for the prevention and treatment of

284 Sofosbuvir and daclatasvir are direct-acting antiviral drugs used to treat chronic hepatitis C virus

285 The host-targeted antiviral drug UV-4B reduces viral replication and promo

286 The use of antiviral drugs was more common in clubfoot cases than i

287 sis of simeprevir, a hepatitis C virus (HCV) antiviral drug, was studied.

288 ACE2 binding compounds and seven antiviral drugs were closely embedded in which two of th

289 AM2 is inhibited by the amantadine class of antiviral drugs, whereas BM2 has no known inhibitors.

290 Here we show that DAS181 (Fludase), an antiviral drug with sialidase activity, potently inhibit

291 ovir and valganciclovir are highly effective antiviral drugs with a well-established role in primary

292 rted a structural platform for the design of antiviral drugs with activities against these viruses or

293 sidered a potential target for the design of antiviral drugs with broad-spectrum activities against t

294 d to novel vaccine approaches or targets for antiviral drugs with broad-spectrum activity.

295 on relationships of 3CLpro for the design of antiviral drugs with broader antiviral activities.

296 of the discovery and characterization of new antiviral drugs with different mechanisms of action and

297 The recurrent and protracted use of antiviral drugs with eventual emergence of drug resistan

298 otion will promote the development of potent antiviral drugs with high specificity and efficiency.

299 sistant to current therapy make the need for antiviral drugs with novel mechanisms of action compelli

300 There are no antiviral drugs with proven clinical efficacy for the tr